Clinical Trial News and Research

RSS

FDA approves new targeted therapy to treat men with advanced prostate cancer

The Food and Drug Administration on Thursday approved abiraterone, a new targeted therapy in the class of androgen receptor blockers.

3 May 2011

Cyberonics initiates first implant of AspireSR product in epilepsy patients

Cyberonics, Inc., a global leader in epilepsy management, today announced the first implant of its AspireSR™ seizure response product on April 27, 2011.

3 May 2011

New non-invasive device can measure brain's precise temperature

Doctors have long sought a way to directly measure the brain's temperature without inserting a probe through the skull. Now researchers have developed a way to get the brain's precise temperature with a device the diameter of a poker-chip that rests on a patient's head, according to findings presented May 1 at the annual meeting of the Pediatric Academic Societies in Denver.

3 May 2011

Diabetes cell implant company approved for Argentina clinical trial

Living Cell Technologies Limited, a company pioneering the development of a cell implant to treat diabetes, has obtained approval to commence a Phase II DIABECELL clinical trial in Buenos Aires, Argentina, DIABECELL's third jurisdiction to date which has approved human trials. Up to eight adult patients with Type 1 diabetes, including those with unstable diabetes and severe hypoglycaemia, will each receive two implants of DIABECELL, three months apart with a dose seeking component. The trial is expected to begin in the second half of this year.

3 May 2011

Boehringer Ingelheim, Eli Lilly receive FDA approval for Tradjenta to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the U.S. Food and Drug Administration approved Tradjenta tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

3 May 2011

Positive Ellex 2RT data demonstrates efficacy in treatment of early Age-Related Macular Degeneration

Ellex Medical Lasers Limited (ASX:ELX) today announced milestone clinical results for its breakthrough Retinal Regeneration Therapy (Ellex 2RT™) for the treatment of Early Age-Related Macular Degeneration (AMD).

2 May 2011

NCI survey: Most people do not know much about clinical trials

Most people don't know much about clinical trials, according to surveys across all races and groups. Yet many members of the Hispanic community fear and distrust doctors, hospitals, and medical research. Part of this distrust may have come from the legacy of enforced sterilizations that Latinas experienced before World War II in Puerto Rico.

2 May 2011

FightSMA to host panel discussions on spinal muscular atrophy

International non-profit organization FightSMA will be hosting highly respected experts from across the country on Thursday, May 5, 2011 for a series of panel discussions, Thriving with SMA: LIVE!.

30 Apr 2011

Bristol-Myers Squibb first quarter net sales increase 5% to $3.3 billion

Bristol-Myers Squibb Company today announced first quarter results that included strong sales and earnings growth, and several key R&D milestones—most notably U.S. regulatory approval for YERVOY. The company also confirmed guidance for the year.

30 Apr 2011

C3 Jian, West China School of Stomatology to create joint CRC to test oral healthcare products

C3 Jian, Inc.'s Board of Directors today announced that the Company has signed an agreement with the West China School of Stomatology at Sichuan University to create a joint Clinical Research Centre to test new oral healthcare products in human clinical trials.

30 Apr 2011

NeurogesX first quarter revenue is $3.2 million for 2011

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for its first quarter ended March 31, 2011.

30 Apr 2011

CEL-SCI receives no objection letter to initiate Phase III clinical trial of Multikine in Canada

CEL-SCI Corporation announced today that the Biologics and Genetic Therapeutics Directorate of Health Canada has issued a final "no objection" letter for CEL-SCI to be able to begin enrollment of patients for a Phase III clinical trial of Multikine in Canada.

30 Apr 2011

FDA approves Abbott's AndroGel for hypogonadism treatment in men

Abbott announced today that the U.S. Food and Drug Administration has approved AndroGel 1.62%, a clear, odorless, gel formulation shown to restore testosterone levels in hypogonadal men with half the volume of gel at the starting dose compared to AndroGel 1%.

30 Apr 2011

Avastin, Lucentis are equally effective for age-related macular degeneration treatment

Age-related macular degeneration, a disease that damages the retina and can destroy central vision, affects approximately 1.6 million Americans. For the past five years, there has been active debate over treatment options for AMD patients because ophthalmologists have not had accurate data regarding the true efficacy of the most commonly used medication.

29 Apr 2011

Researchers report Avastin is effective as Lucentis for AMD treatment

Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration, is as effective as the Food and Drug Administration-approved drug Lucentis for the treatment of AMD.

29 Apr 2011

New PET imaging clinical trial to improve early esophageal, lung cancer detection

Can a simple imaging test help predict the success of cancer treatment, even before the treatment is complete? To begin to answer this question, a new National Cancer Institute-funded clinical trial is using a novel PET imaging technique that could improve the early detection of tumor growth during treatment for esophageal and lung cancer.

29 Apr 2011

Ramipril can effectively reduce risk of ESRD in obese patients

The angiotensin-converting enzyme inhibitor drug, ramipril, is particularly effective in lowering the risk of end-stage renal disease in obese patients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

29 Apr 2011

CEL-SCI initiates Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Meenakshi Mission Hospital and Research Centre in Madurai, Tamil Nadu, India, the first clinical site in India.

28 Apr 2011

FDA accepts OncoMed's IND filing for OMP-18R5 in Phase 1 clinical trial for advanced solid tumors

OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells or tumor-initiating cells, today announced that the FDA has accepted an IND filing for OMP-18R5, which allows OncoMed to commence Phase 1 clinical testing.

28 Apr 2011

FDA approves orphan drug designation for Cytrx’s INNO-206 to treat pancreatic cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its tumor-targeting pro-drug candidate INNO-206 has been approved for orphan drug designation for the treatment of patients with pancreatic cancer by the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA). CytRx holds the exclusive worldwide development and commercialization rights to INNO-206.

28 Apr 2011

Clinical Trial News and Research

FDA approves new targeted therapy to treat men with advanced prostate cancer

Cyberonics initiates first implant of AspireSR product in epilepsy patients

New non-invasive device can measure brain's precise temperature

Diabetes cell implant company approved for Argentina clinical trial

Boehringer Ingelheim, Eli Lilly receive FDA approval for Tradjenta to treat type 2 diabetes

Positive Ellex 2RT data demonstrates efficacy in treatment of early Age-Related Macular Degeneration

NCI survey: Most people do not know much about clinical trials

FightSMA to host panel discussions on spinal muscular atrophy

Bristol-Myers Squibb first quarter net sales increase 5% to $3.3 billion

C3 Jian, West China School of Stomatology to create joint CRC to test oral healthcare products

NeurogesX first quarter revenue is $3.2 million for 2011

CEL-SCI receives no objection letter to initiate Phase III clinical trial of Multikine in Canada

FDA approves Abbott's AndroGel for hypogonadism treatment in men

Avastin, Lucentis are equally effective for age-related macular degeneration treatment

Researchers report Avastin is effective as Lucentis for AMD treatment

New PET imaging clinical trial to improve early esophageal, lung cancer detection

Ramipril can effectively reduce risk of ESRD in obese patients

CEL-SCI initiates Multikine Phase III trial in head and neck cancer

FDA accepts OncoMed's IND filing for OMP-18R5 in Phase 1 clinical trial for advanced solid tumors

FDA approves orphan drug designation for Cytrx’s INNO-206 to treat pancreatic cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News